대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Management of intractable uremic pruritus
저자	Hon-Yen Wu
출판정보	2021; 2021(1):
키워드
초록	Uremic pruritus is one of the most common and bothersome symptoms in patients with end stage renal disease and chronic kidney disease. Uremic pruritus affects 40% to 85% of patients receiving hemodialysis and 25% to 60% of patients receiving peritoneal dialysis. Most patients with uremic pruritus experience a prolonged and relapsing course. Uremic pruritus significantly affects the quality of life in multiple aspects, including mood, sleep, and social relationships. The effect of therapy on uremic pruritus is often unsatisfactory. The pathophysiology of uremic pruritus is not completely understood. A complex interplay among cutaneous biology, the nervous system, and the immune system has been implicated, with the involvement of various inflammatory mediators, neurotransmitters, and opioids. Clinical trials on the treatment of uremic pruritus have been mostly small in scale and have reported inconsistent results. Correct assessment and diagnosis, optimization of metabolic profiles and dialysis regimens, proper skin care and protection, selection of appropriate topical and oral medications, and monitoring of the side effects of drugs are all important in the management of uremic pruritus. Recent evidence shows that gabapentinoids, nalfurafine, and difelikefalin are effective in relieving uremic pruritus in hemodialysis patients. Antihistamines, mast cell stabilizers, leukotriene receptor antagonists, activated charcoal, and phototherapy may also be therapeutic options, although more trial results are necessary. With advances in exploring the pathophysiology of pruritus and new findings from the latest clinical trials, more treatment options for uremic pruritus can be expected.
원문(PDF)	PDF 원문보기

목록

위로가기